The human body is obviously not a mouse - we obviously have size differences by multiples - imagine the poor mouse having a suppository! I get the human tumour but this can be grown in the lab why put them in a mouse - how is that relevant to a human? if the compound attacks the tumour in a test tube then what is the point of putting that tumour into a mouse who is then given the compound/s?
I guess safety wise its a good idea to test it on a poor mouse before using it on a human but the human tumour is still a human tumour - it came from a human (presumably), putting it into a mouse with the differences in anatomy and physiology and diet and environment and DNA etc etc etc I would think is not a great indicator of how it would behave in a human - safety yes no argument. (having said that sometimes this is not the case in that what doesn't hurt a mouse can sometimes hurt a human as described in the below article)
Why Drugs Tested in Mice Fail in Human Clinical Trials
https://sitn.hms.harvard.edu/flash/2020/why-drugs-tested-in-mice-fail-in-human-clinical-trials/
- Forums
- ASX - By Stock
- NOX
- Ann: Veyonda Survival Advantage in LuPSMA Therapy Confirmed
Ann: Veyonda Survival Advantage in LuPSMA Therapy Confirmed, page-20
-
- There are more pages in this discussion • 9 more messages in this thread...
You’re viewing a single post only. To view the entire thread just sign in or Join Now (FREE)
Featured News
KAI
Pilbara Minerals buys land off Kairos part of its York gold project for $20M – and a 2% royalty on any PLS gold sales
STX
Strike hands $48.5M contract to Clarke Energy to produce 20x 4.5MW gas engines for Sth Erregulla
TG1
TechGen Metals kicks off airborne geophys survey at Sally Downs copper play – a first for the permit
Add NOX (ASX) to my watchlist
|
|||||
Last
6.9¢ |
Change
-0.003(4.17%) |
Mkt cap ! $20.16M |
Open | High | Low | Value | Volume |
6.9¢ | 6.9¢ | 6.9¢ | $3.085K | 44.70K |
Buyers (Bids)
No. | Vol. | Price($) |
---|---|---|
1 | 22852 | 6.9¢ |
Sellers (Offers)
Price($) | Vol. | No. |
---|---|---|
7.0¢ | 1310 | 1 |
View Market Depth
No. | Vol. | Price($) |
---|---|---|
1 | 22852 | 0.069 |
1 | 10000 | 0.068 |
2 | 47278 | 0.066 |
1 | 15000 | 0.065 |
2 | 89000 | 0.063 |
Price($) | Vol. | No. |
---|---|---|
0.070 | 1310 | 1 |
0.072 | 1237 | 1 |
0.074 | 50000 | 1 |
0.076 | 4999 | 1 |
0.079 | 12000 | 1 |
Last trade - 15.09pm 02/08/2024 (20 minute delay) ? |
Featured News
MND
Albemarle lithium downsize burns $200M hole in Monadelphous's pocket as latter's contracts terminated
GML
Gateway Mining sells WA Eastern Montague gold project to Brightstar for $14M – half of that in shares
NOX (ASX) Chart |